On September 30, AKESO fell 3.86% in regular trading, trading at 102.7 HKD/share, with turnover of 169 million HKD. The decline came as investors locked in gains following the stock's 15.54% surge in the prior session, which had added over 13 billion HKD in market capitalization.

The previous session's rally was triggered by AstraZeneca's announcement of a 2 billion USD strategic investment in Summit Therapeutics, subscribing for Summit preferred shares at 18.36 USD per share — an 18.6% premium to Summit's closing price. The core asset underlying this transaction is ivonescimab (branded Yidafang), a first-in-class PD-1/VEGF bispecific antibody developed by AKESO and previously licensed to Summit for up to 5 billion USD in total potential milestone payments. The deal was widely viewed as a major endorsement of ivonescimab's global commercial value by a top multinational pharma company. Southbound capital also reduced its AKESO holdings in the prior session, reflecting selective profit realization at elevated levels. Multiple international investment banks maintain Buy ratings, with CICC raising its target price to 130 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)